Compare FA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | VERA |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.0B |
| IPO Year | 2021 | 2021 |
| Metric | FA | VERA |
|---|---|---|
| Price | $21.21 | $28.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | $26.00 | ★ $74.20 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,574,389,000.00 | N/A |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $6.69 | $863.11 |
| P/E Ratio | $193.55 | ★ N/A |
| Revenue Growth | ★ 83.02 | N/A |
| 52 Week Low | $8.82 | $23.05 |
| 52 Week High | $25.15 | $56.05 |
| Indicator | FA | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 42.13 |
| Support Level | $19.90 | $26.38 |
| Resistance Level | $21.43 | $36.95 |
| Average True Range (ATR) | 0.72 | 1.66 |
| MACD | 0.32 | 0.16 |
| Stochastic Oscillator | 87.10 | 35.68 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.